-
Uncategorized7 days ago
A new way to sell weight loss drugs?
A new way to sell weight loss drugs?
-
Uncategorized7 days ago
Advancing the Manufacture of Patient Accessible Cell and Gene Therapies at Place-of-Care
A partnership involving a medical school, a non-profit organization, and a biotech company have formed a partnership for the development and manufacture of an accessible and...
-
Uncategorized7 days agoLilly beefs up neuroscience pipeline with $6.3B Centessa buyout
The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with Takeda and Eisai.
-
Uncategorized7 days ago
Colorado biotech Ambrosia lands $100M for oral GLP-1
Colorado biotech Ambrosia lands $100M for oral GLP-1
-
Uncategorized7 days ago
Astellas doesn’t pick up AviadoBio’s gene therapy, but nonprofit funding will move it forward
In a sign of the times for gene therapy, Astellas did not take up its option on AviadoBio’s frontotemporal dementia treatment, the UK biotech company disclosed...
-
Uncategorized7 days ago
Celiac Disease Study Reveals Fiber Benefits Depend on Gut Microbiome
The autoimmune disorder celiac disease results in mucosal inflammation and injury of the small intestine, driven by dietary gluten, resulting in a wide range of varied...
-
Uncategorized7 days agoSTAT+: Baby KJ scientists hit road bump in quest to scale custom gene editor
The scientists behind treating Baby KJ say they’ve hit a stumbling block in their efforts to create more custom gene editing treatments for children with rare...
-
Uncategorized7 days ago
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease...
-
Uncategorized7 days ago
Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
Irish antibiotic specialist Iterum Therapeutics has started winding down its operations, citing limited cash amid the expensive commercialization of its only approved product, Orlynvah.
-
Uncategorized7 days agoSTAT+: Pharmalittle: We’re reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where...
BioNTech to shutter Singapore HQ after ‘comprehensive review’
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
